Hexagon Bio, a biopharmaceutical company developing new cancer treatments, has raised $62 million in Series C funding to advance its antibody-drug conjugate (ADC) pipeline.
The funding round was led by The Column Group, with participation from existing investors, including Nextech Invest, Deviation Capital, 8VC and Canada Pension Plan Investment Board (CPP Investments).
The company will use the funds to support the development of HEX-360, a HER2-targeting ADC designed to treat cancer. Hexagon Bio expects to begin Phase 1 clinical trials in the first half of 2027. The funding will also support the development of additional drug candidates using its proprietary ADC platform.
“This financing reflects our conviction that the next generation of ADCs will be focused on novel payloads that can transform the treatment paradigm for many cancers,” said Maureen Hillenmeyer, Ph.D., co-founder and Chief Executive Officer of Hexagon Bio. “This capital allows us to rapidly transition into a clinical-stage company and brings us one step closer to providing much-needed therapeutic options for patients who have progressed on or cannot tolerate current ADCs.”
“To push the boundaries of what ADCs can achieve for patients, the industry needs to look beyond existing payloads,” said Scott Garland, Chairman of Hexagon Bio’s Board of Directors. “Hexagon’s rapid progress in advancing HEX-360 toward the clinic, while simultaneously discovering orthogonal payload mechanisms, demonstrates the unique power of their platform.”
Antibody-drug conjugates combine antibodies with cancer-killing drugs to target and attack cancer cells. However, some cancer cells develop resistance to existing ADC treatments, limiting their effectiveness. Many currently available ADCs rely on payloads such as topoisomerase and tubulin inhibitors.
HEX-360 uses a novel translation inhibitor payload designed to block the production of proteins that cancer cells need to grow. The approach aims to overcome resistance to existing ADC treatments and provide another option for patients with cancer.
Preclinical studies of HEX-360 presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting demonstrated promising results. The candidate showed strong activity in laboratory and animal models, including models resistant to topoisomerase inhibitors. It also showed promising tolerability in studies in rats and non-human primates
The drug candidate is currently undergoing studies required before clinical trials can begin. Hexagon Bio has also established a clinical advisory board of breast cancer experts to support HEX-360’s development.
Founded to discover new drug payloads from natural products, Hexagon Bio uses a proprietary platform to identify molecules from microbial genomes that could be developed into cancer treatments. The company aims to develop next-generation ADCs that address treatment resistance and improve outcomes across different cancer types.
The latest funding will help Hexagon Bio advance its clinical development plans and expand its pipeline of cancer therapies using novel drug mechanisms.
